New data from NHS England highlights the transformative impact of stereotactic ablative radiotherapy on prostate cancer treatment efficiency. Precision radiotherapy reduces the number of required treatment sessions from 20 to just 5, representing a remarkable 75% decrease in hospital visits for eligible patients.
This dramatic reduction in treatment frequency translates to substantial benefits for both patients and healthcare infrastructure. Fewer hospital visits mean reduced travel burden, improved quality of life during active treatment, and decreased strain on clinical resources. Importantly, this efficiency gain does not compromise therapeutic outcomes; clinical trials validate that SABR maintains or improves cancer control rates compared to conventional external beam radiotherapy.
The focused beam technology delivers concentrated radiation doses to tumors while protecting adjacent healthy tissues, thereby reducing long-term side effects that commonly accompany prolonged radiotherapy courses.
Was this article helpful?
